| Code | CSB-RA808531MB3HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to REGN-7999, targeting TMPRSS6 (transmembrane serine protease 6), also known as matriptase-2. TMPRSS6 is a type II transmembrane serine protease that plays a critical role in systemic iron homeostasis by cleaving membrane-bound hemojuvelin, thereby suppressing hepcidin production in the liver. Hepcidin is the master regulator of iron metabolism, controlling iron absorption and release from stores. Dysregulation of the TMPRSS6-hepcidin axis is implicated in various iron disorders, including iron-refractory iron deficiency anemia (IRIDA) and conditions of iron overload such as hereditary hemochromatosis and β-thalassemia.
REGN-7999 represents a therapeutic antibody approach designed to inhibit TMPRSS6 activity, thereby increasing hepcidin levels to reduce iron absorption and mobilization. This biosimilar antibody provides researchers with a valuable tool for investigating TMPRSS6 biology, studying iron regulatory pathways, and exploring potential therapeutic interventions for iron metabolism disorders in preclinical models.
There are currently no reviews for this product.